Vitamin D signaling is modulated on multiple levels in health and disease
- PMID: 16406653
- DOI: 10.1016/j.mce.2005.11.039
Vitamin D signaling is modulated on multiple levels in health and disease
Abstract
Vitamin D signaling is dependent on the availability and turnover of the active Vitamin D receptor (VDR) ligand 1,25-dihydroxycholecalciferol and on the efficiency of VDR transactivation. Activating and inactivating secosteroid metabolizing p450 enzymes, e.g. 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase, are responsible for ligand availability on the basis of substrate production in the skin and of nutritional intake of precursors. Net availability of active hormone depends on the delivery of substrate and the balance of activating and inactivating enzymes. 1Alpha-hydroxylase is the critical activating enzyme. It is expressed in the kidney for systemic supply and in target tissues for local secosteroid activation. It is upregulated in the kidney by low calcium intake and parathyroid hormone, downregulated by phosphatonins and proinflammatory signal transduction. Transactivation of VDR depends on the correct molecule structure, effective nuclear translocation and the presence of the unliganded heterodimer partner retinoid X-receptor (RXR) and other nuclear cofactors. Rapid Vitamin D-dependent membrane associated effects and consecutive second messenger activation exert an own pattern of gene regulation. A membrane receptor for these effects is hypothesized but not yet identified. Rickets is the long known clinical syndrome of impaired Vitamin D signaling due to Vitamin D3 deficiency. It can be caused by inherited defects of the cascade, nutritional deficits, lack of sunlight exposure, malabsorption and underlying diseases like chronic inflammation. It has been shown during the last decades that many modifiers of Vitamin D signaling are targets of disease in terms of inherited and acquired syndromes and that Vitamin D signaling is modulated at multiple levels and is more complex than mere mechanistic ligand/receptor/DNA interaction.
Similar articles
-
1alpha,25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action.Endocr Regul. 2004 Mar;38(1):29-38. Endocr Regul. 2004. PMID: 15147236 Review.
-
Vitamin D physiology.Prog Biophys Mol Biol. 2006 Sep;92(1):4-8. doi: 10.1016/j.pbiomolbio.2006.02.016. Epub 2006 Feb 28. Prog Biophys Mol Biol. 2006. PMID: 16563471 Review.
-
Altered gene expression profile in the kidney of vitamin D receptor knockout mice.J Cell Biochem. 2003 Jul 1;89(4):709-19. doi: 10.1002/jcb.10547. J Cell Biochem. 2003. PMID: 12858337
-
The impact of functional vitamin D(3) receptor conformations on DNA-dependent vitamin D(3) signaling.Mol Pharmacol. 2000 Feb;57(2):375-84. Mol Pharmacol. 2000. PMID: 10648648
-
Vitamin D.Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28. doi: 10.1152/ajprenal.00336.2004. Am J Physiol Renal Physiol. 2005. PMID: 15951480 Review.
Cited by
-
Vitamin D: something new under the sun.Clin Kidney J. 2012 Aug;5(4):285-7. doi: 10.1093/ckj/sfs080. Clin Kidney J. 2012. PMID: 25874081 Free PMC article. No abstract available.
-
The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson's disease.Transl Neurodegener. 2020 Sep 1;9(1):34. doi: 10.1186/s40035-020-00213-2. Transl Neurodegener. 2020. PMID: 32867847 Free PMC article. Review.
-
Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial.Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):280-91. doi: 10.1158/1055-9965.EPI-09-0448. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20056649 Free PMC article. Clinical Trial.
-
Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial.Cancer Prev Res (Phila). 2011 Oct;4(10):1645-54. doi: 10.1158/1940-6207.CAPR-11-0105. Epub 2011 Jun 30. Cancer Prev Res (Phila). 2011. PMID: 21724580 Free PMC article. Clinical Trial.
-
Vitamin d receptor activators and clinical outcomes in chronic kidney disease.Int J Nephrol. 2011;2011:419524. doi: 10.4061/2011/419524. Epub 2011 May 15. Int J Nephrol. 2011. PMID: 21647319 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical